{"id":21261,"date":"2013-04-01T11:52:31","date_gmt":"2013-04-01T11:52:31","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=21261"},"modified":"2013-04-03T09:36:34","modified_gmt":"2013-04-03T09:36:34","slug":"once-daily-option-for-paediatric-use-of-darunavirritonavir","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/21261","title":{"rendered":"Once-daily option for paediatric use of darunavir\/ritonavir"},"content":{"rendered":"<p><strong>On 1 February 2013, the FDA approved revisions to the darunavir (Prezista) tablet and oral suspension label to include paediatric use.<\/strong><\/p>\n<p>This included once daily dosing in treatment-na\u00efve subjects 3 to less than 18 years of age and once-daily dosing in treatment-experienced subjects 3 to less than 18 years of age with no darunavir resistance associated substitutions.<\/p>\n<p>Weight-based dosing tables are included by age, weight and treatment experience.<\/p>\n<p>For full details please see the full label and\/or online infromation from the FDA list serve.<\/p>\n<p>Source: FDA list serve. Prezista (darunavir) tablet and oral suspension: pediatric dosing. (1 February 2013).<\/p>\n<p><a href=\"http:\/\/www.fda.gov\/ForConsumers\/ByAudience\/ForPatientAdvocates\/HIVandAIDSActivities\/ucm337778.htm\">http:\/\/www.fda.gov\/ForConsumers\/ByAudience\/ForPatientAdvocates\/HIVandAIDSActivities\/ucm337778.htm<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 1 February 2013, the FDA approved revisions to the darunavir (Prezista) tablet and oral suspension label to include paediatric use. This included once daily dosing in treatment-na\u00efve subjects 3 to less than 18 years of age and once-daily dosing &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[32],"tags":[],"class_list":["post-21261","post","type-post","status-publish","format-standard","hentry","category-paediatric-care"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/21261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=21261"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/21261\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=21261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=21261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=21261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}